GVS
870976
Hangzhou CNCR-IT
300250
Shanghai Newtouch Software
688590
4
Ucap Cloud Information Technology Co.,Ltd
688228
5
Yangtze Optical Electronic
688143
US Stock MarketDetailed Quotes
ADAP Adaptimmune Therapeutics
- 0.592
- +0.015+2.56%
Close Jan 24 16:00 ET
- 0.590
- -0.002-0.32%
Post 19:55 ET
151.46MMarket Cap-3.54P/E (TTM)
0.610High0.559Low747.14KVolume0.580Open0.577Pre Close440.33KTurnover0.38%Turnover RatioLossP/E (Static)255.88MShares2.05052wk High1.89P/B116.10MFloat Cap0.53252wk Low--Dividend TTM196.14MShs Float21.570Historical High--Div YieldTTM8.86%Amplitude0.420Historical Low0.589Avg Price1Lot Size
Trending Stocks
Discussing
U.S.-China talks spark interest, no more inflation?
🎙️Discussion: 1. How will Trump's China policies affect Chinese assets? 2. Which sectors might benefit as U.S. inflation risks decline?
Moomoo News Global
Dec 9, 2024 20:23
China Will Adopt a "Moderately Accommodative" Monetary Policy in the Next Year, The First Shift to Easing Since 2011
Adaptimmune Therapeutics Stock Forum
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
Monday, 13th January at 8:00 am
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets
Adaptimmune Allo-T program to be featured at the Biotech ShowCase(TM) and the
Wuxi Global Forum ...
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8,...
so the spike in cash is from financing, fyi
No comment yet